US2009270654A1PendingUtilityA1
Hepatic fibrosis inhibitor
Est. expiryApr 14, 2028(~1.7 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 1/16A61K 31/085A61K 31/216
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6, or alkoxycarbonyl group with a carbon number of 2 to 6.
Claims
exact text as granted — not AI-modified1 . A hepatic fibrosis inhibitor comprising, as an effective ingredient, hydroquinone derivative containing a compound represented by Formula (1):
wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6, or alkoxycarbonyl group with a carbon number of 2 to 6.
2 . The hepatic fibrosis inhibitor set forth in claim 1 , wherein said compound represented by said chemical formula (1) is 2,3,5-trimethyl hydroquinone-1-hexylether or 2,3,5-trimethyl hydroquinone-1-hexylether 4-acetate.Join the waitlist — get patent alerts
Track US2009270654A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.